Cargando…
Effectiveness and safety of Tiaogan formula in the treatment of coronary heart disease: A protocol for systematic review and meta-analysis
The morbidity and mortality of coronary heart disease (CHD) has remained high, which greatly increases people’s economic burden. Several studies have showed that Tiaogan formula (TGF), as a kind of Chinese herbal medicine, was of benefit to relieving angina pectoris symptoms and improving the qualit...
Autores principales: | Mingtai, Chen, Guofu, Zhong, Junteng, Chen, Ling, Men, Jienan, Luan, Zhihao, Luo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771251/ https://www.ncbi.nlm.nih.gov/pubmed/36550848 http://dx.doi.org/10.1097/MD.0000000000032237 |
Ejemplares similares
-
Effectiveness and safety of Xinkeshu on coronary artery disease patients combined with anxiety and depression symptoms after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
por: Chen, Mingtai, et al.
Publicado: (2021) -
Effectiveness and safety of Shugan Jianpi (SGJP) formula in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review and meta-analysis of randomized controlled trials
por: Chen, Mingtai, et al.
Publicado: (2021) -
Investigating the mechanisms of Modified Xiaoyaosan (tiaogan-liqi prescription) in suppressing the progression of atherosclerosis, by means of integrative pharmacology and experimental validation
por: Chen, Mingtai, et al.
Publicado: (2021) -
A systematic review of the effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris
por: Chen, Mingtai, et al.
Publicado: (2019) -
Buzhong Tiaogan Formula for delaying colorectal liver metastasis (liver depression spleen deficient type): A multicenter randomized controlled trial: A study protocol
por: Wang, Zhi-Jie, et al.
Publicado: (2021)